{{Rsnum
|rsid=2784917
|Gene=SLIT1
|Chromosome=10
|position=98928942
|Orientation=minus
|GMAF=0.3246
|Gene_s=ARHGAP19-SLIT1,SLIT1
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=137
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 66.2 | 29.2 | 4.6
| HCB | 28.9 | 51.1 | 20.0
| JPT | 28.9 | 48.9 | 22.2
| YRI | 28.6 | 46.0 | 25.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 28.9 | 51.1 | 20.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2784917
|Name_s=
|Gene_s=SLIT1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: TT genotype Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with increased gene expression of WNT5 (P = 7 ? 10?8), and etoposide toxicity (P = 5 ? 10?5) based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs278917, rs10061997, rs12190776, and rs9730073 were all significant predictors of etoposide IC50, and accounted for 40% of the etoposide IC50 variation in Yorubans. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): P = 5 ? 10?5. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109516
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2784917
|overall_frequency_n=77
|overall_frequency_d=128
|overall_frequency=0.601562
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}